

## Regulatory Information

## Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2010

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (May 5, 2010 – 06:00 pm) – As of April 30, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

	April 30, 2010
Shares outstanding	216,144,241
Exercisable voting rights	226,507,017
Total potential voting rights, including rights attached to shares held in treasury and under the liquidity contract.	234,449,995

\_\_\_\_\_

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to correct myopia, hyperopia, presbyopia and astigmatism. Its flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Essilor<sup>®</sup>, Definity<sup>®</sup> and Xperio<sup>™</sup>. Based in France, the company reported consolidated revenue of €3.2 billion in 2009, with 34,700 employees and operations in 100 countries. For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

\_\_\_\_\_

Investor Relations and Financial Communications <u>www.essilor.com</u>

Phone: +33 (0)1 49 77 42 16